• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

CFI-400437 dihydrochloride

CAS No. 1247000-76-5

CFI-400437 dihydrochloride ( —— )

产品货号. M23418 CAS No. 1247000-76-5

CFI-400437 是一种选择性且有效的 polo 样激酶 4 (PLK4) 抑制剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1644 有现货
10MG ¥2518 有现货
25MG ¥4083 有现货
50MG ¥5701 有现货
100MG ¥7443 有现货
500MG ¥14850 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    CFI-400437 dihydrochloride
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    CFI-400437 是一种选择性且有效的 polo 样激酶 4 (PLK4) 抑制剂。
  • 产品描述
    CFI-400437 is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
  • 体外实验
    ——
  • 体内实验
    (1E)-CFI-400437 (25 mg/kg; intraperitoneal injection; daily for 21 days) dihydrochloride shows effective in a mouse xenograft model of tumor growth.The plasma levels of (1E)-CFI-400437 (50 mg/kg; IP; mice) dihydrochloride shows a Cmax of 92 ng/mL and AUC of 190 ng?h/mL, respectively. The mouse plasma protein binding measurement for (1E)-CFI-400437 is 99%, i.e., unbound compound in plasma is 1%. Animal Model:6-8 week old female CB-17 SCID mice (MDA-MB-468 mouse xenograft model)Dosage:25 mg/kg Administration:Intraperitoneal injection; daily for 21 days Result:Effective in a mouse xenograft model of tumor growth.In this study, (1E)-CFI-400437 is weighed and suspended in PEG400:water (30:70) and sonicated at rt for 30 min. The compound is dispensed in aliquots and stored at ?20 C° for the duration of the study, and each aliquot was thawed at room temperature before each dose.
  • 同义词
    ——
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    PLK
  • 受体
    PLK4
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1247000-76-5
  • 分子量
    565.5
  • 分子式
    C29H30Cl2N6O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO:5 mM
  • SMILES
    CN1CCN(CC1)C2=NC=C(C=C2)/C=C/C3=C4C=CC(=CC5=C(NC6=C5C=C(C=C6)OC)O)C=C4N=N3.Cl.Cl
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Suri A , Bailey A W , Tavares M T , et al. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer[J]. International Journal of Molecular Sciences, 2019, 20(9).
产品手册
关联产品
  • Rigosertib sodium (b...

    Rigosertib (ON-01910) 是一种 PLK1 非 ATP 竞争性抑制剂,IC50 为 9 nM。

  • Poloxin-2

    Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.

  • Centrinone-B

    Centrinone-B (LCR-323) 是一种有效的,高度选择性的 PLK4 抑制剂,Ki 值为 0.59 nM。